Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tafasitamab + lenalidomide + rituximab versus placebo + lenalidomide + rituximab in relapsed/refractory follicular lymphoma or marginal zone lymphoma
2020-004407-13Phase 3Active
- Sponsor
- Incyte
- Start
- Apr 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of tafasitamab, lenalidomide and rituximab in follicular lymphoma (FL) and marginal zone B-cell lymphoma (MZL) (2 arms), sponsored by Incyte. Primary endpoint: Progression-free survival by investigator assessment in the follicular lymphoma population. Started Apr 2021; status: active.
02
Drugs
tafasitamablenalidomiderituximab
03
Conditions
follicular lymphoma (FL)marginal zone B-cell lymphoma (MZL)
Beyond the preview
Go deeper on 2020-004407-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-004407-13.